Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 4:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 91 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus Type 2 With Hyperglycemia Clear all
Recruiting Phase 4 Interventional Accepts healthy volunteers

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

NCT06657209
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
Interventions
Insulin resistance testing, OGTT, Fat biopsy, DXA scan, MRI, 1H-MRS, Tirzepatide, Pioglitazone
Procedure · Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 10, 2026, 4:48 AM EDT
Withdrawn Phase 3 Interventional

A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus

NCT02106364
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Peglispro, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Zephyrhills, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 10, 2026, 4:48 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Blood Pressure Medications on Metabolism

NCT00642434
View directory record Official record
Conditions
Diabetes
Interventions
carvedilol, metoprolol
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
45 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 10, 2026, 4:48 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea

NCT00713830
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Sulfonylurea, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 10, 2026, 4:48 AM EDT
Completed Phase 4 Interventional Results available

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

NCT01378117
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia
Interventions
Sitagliptin, glargine, lispro
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 10, 2026, 4:48 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

NCT01234649
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
Interventions
Metformin XR plus placebo, Metformin XR plus liraglutide
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 10, 2026, 4:48 AM EDT
Completed Phase 3 Interventional Results available

Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.

NCT00570739
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
Interventions
Metformin HCl and Colesevelam Placebo, Metformin HCl tablets and Colesevelam tablets, Colesevelam placebo, Colesevelam
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 79 Years
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Los Gatos, California • Tarzana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 10, 2026, 4:48 AM EDT
Not listed Not applicable Interventional

Evaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People With T2 Diabetes

NCT04843527
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
FreeStyle Libre System, FreeStyle Libre System plus food app
Device
Lead sponsor
Abbott Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Boston, Massachusetts • Detroit, Michigan • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 10, 2026, 4:48 AM EDT
Active, not recruiting Phase 2 Interventional

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

NCT05067621
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
Interventions
Semaglutide Pen Injector, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
10 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 10, 2026, 4:48 AM EDT
Terminated Not applicable Interventional

Control:Diabetes Pilot Study I

NCT04158921
View directory record Official record
Conditions
Insulin Treated Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 1
Interventions
Control:Diabetes mobile app
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 10, 2026, 4:48 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

NCT01719003
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hyperglycemia
Interventions
Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd, Empagliflozin high dose qd, Empagliflozin low dose bid, Empagliflozin high dose bid
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
41
States / cities
Birmingham, Alabama • Manley Hot Springs, Alaska • Glendale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 10, 2026, 4:48 AM EDT
Completed No phase listed Observational

mRNA Based-Covid-19 Vaccine Effects on Blood Glucose Levels

NCT04923386
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Hyperglycemia, Vaccine Adverse Reaction
Interventions
None (not interventional)
Other
Lead sponsor
Levenson, David I., M.D.
Individual
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Oct 10, 2026, 4:48 AM EDT
Recruiting Not applicable Interventional

Mechanisms of Fatigability With Diabetes

NCT04442451
View directory record Official record
Conditions
Pre-diabetes, Type 2 Diabetes
Interventions
Control Exercise, Blood Flow Restriction Exercise
Other
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 10, 2026, 4:48 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

NCT07215312
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY3938577, Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Tucson, Arizona • Spring Valley, California • Tustin, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 10, 2026, 4:48 AM EDT
Completed Phase 4 Interventional Results available

Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)

NCT00979628
View directory record Official record
Conditions
Type 2 Diabetes, Hyperglycemia
Interventions
sliding scale regular insulin (SSRI), Basal Bolus, Basal Plus
Drug
Lead sponsor
Guillermo Umpierrez, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Atlanta, Georgia • Decatur, Georgia • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 10, 2026, 4:48 AM EDT
Completed Not applicable Interventional Results available

Time in Glucose Hospital Target

NCT05135676
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Blinded CGM, real-time CGM
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 10, 2026, 4:48 AM EDT
Completed Phase 2 Interventional

Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes

NCT00065676
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
Quercetin, Placebo
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 10, 2026, 4:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)

NCT02971202
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance
Interventions
Hyperinsulinemic, euglycemic clamp, 20% dextrose
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years to 51 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 10, 2026, 4:48 AM EDT
Completed No phase listed Observational

CGM Utilization With IV Insulin EndoTool and Subcutaneous Insulin in the Neuro ICU

NCT05857007
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hyperglycemia
Interventions
Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 10, 2026, 4:48 AM EDT
Completed Phase 3 Interventional Results available

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

NCT04460326
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
Insulin glargine, NovoLog, Insulin Fiasp, Standard carbohydrate diet
Drug · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 10, 2026, 4:48 AM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.

NCT03389100
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Pre-diabetes
Interventions
18F-MK6240 injection
Drug
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 69 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 10, 2026, 4:48 AM EDT
Completed Phase 4 Interventional Results available

Linagliptin Inpatient Trial

NCT02004366
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Linagliptin, Basal Bolus, Linagliptin + 50% Glargine dose on discharge, Linagliptin + 80% Glargine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 10, 2026, 4:48 AM EDT
Completed Phase 4 Interventional Results available

ADA Linagliptin in Long Term Care

NCT02061969
View directory record Official record
Conditions
Diabetes
Interventions
linagliptin, insulin glargine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 10, 2026, 4:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Colesevelam HCl On Bile Acid Kinetics

NCT00476710
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Colesevelam HCl
Drug
Lead sponsor
KineMed
Industry
Eligibility
40 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 10, 2026, 4:48 AM EDT